Product image of Lanreotid Zentiva (Lanreotide) supplied by GNH India

Lanreotid Zentiva

Active Ingredient:
Lanreotide
Origin:
EU

Lanreotid Zentiva (Lanreotide)

Lanreotide, the active ingredient in Lanreotid Zentiva, is a somatostatin analog presented as an injectable solution for subcutaneous use. It treats acromegaly and hormone‑secreting neuroendocrine tumors in adult patients, helping to control excess growth hormone and related symptoms.

GNH India supplies Lanreotid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product is manufactured under EU GMP standards and is distributed to meet the needs of specialist care units across multiple continents globally.

Manufacturer / TM Owner

Zentiva, K.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lanreotide is employed in disorders driven by excess growth hormone secretion or hormone‑producing neuroendocrine tumors.

  • Acromegaly: lowers serum growth hormone and IGF‑1 levels, reducing disease activity.
  • Carcinoid syndrome (functional neuroendocrine tumors): diminishes flushing and diarrhoea by suppressing hormone release.
  • Gastroenteropancreatic neuroendocrine tumors: controls hormone‑related symptoms and may slow tumor progression.

How It Works

  • Lanreotide binds with high affinity to somatostatin receptor subtypes SSTR2 and SSTR5 on target cells. This interaction inhibits adenylate cyclase activity, reducing cyclic AMP production and suppressing the secretion of growth hormone, insulin, glucagon, and various gastrointestinal hormones. The resulting decrease in circulating growth hormone leads to lower insulin‑like growth factor‑1 (IGF‑1) concentrations, while inhibition of other hormones alleviates symptoms associated with hormone‑secreting neuroendocrine tumors.

Side Effects

Lanreotide may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects

  • Injection site pain: mild discomfort or erythema at the injection site.
  • Diarrhoea: loose stools occurring shortly after dosing.
  • Nausea: transient feeling of sickness.
  • Abdominal pain: cramping or discomfort in the abdomen.
  • Headache: mild to moderate head pain.
  • Hyperglycaemia: elevated blood glucose levels, especially in diabetic patients.

Serious or Rare Side Effects

  • Gallstone formation: biliary sludge or stones requiring medical attention.
  • Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain.
  • Severe allergic reaction: anaphylaxis, angioedema, or urticaria.
  • Cardiac arrhythmia: irregular heart rhythm observed in rare cases.

Precautions & Warnings

Before initiating Lanreotide therapy, several precautionary measures should be considered.

  • Monitor glucose: lanreotide can alter blood‑sugar levels; regular monitoring is advised.
  • Assess gallbladder: patients with a history of gallstones should be evaluated due to increased risk.
  • Evaluate liver function: use with caution in hepatic impairment and adjust therapy as needed.
  • Watch for hypersensitivity: discontinue immediately if signs of severe allergic reaction appear.
  • Pregnancy and lactation: safety not established; avoid unless the potential benefit justifies the risk.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Lanreotide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

  • Cyclosporine: may increase lanreotide levels, raising risk of adverse effects.
  • Octreotide: concurrent use can lead to additive hormonal suppression and higher incidence of gallstones.
  • Diazoxide: may reduce the therapeutic effect of lanreotide on growth hormone control.

Moderate Interactions (Monitor Closely)

  • Antidiabetic agents: lanreotide may worsen hyperglycaemia, requiring dose adjustments.
  • Concomitant somatostatin analogs: increased risk of gastrointestinal side effects and gallstone formation.
  • Medications affecting gastric emptying: may alter absorption of oral drugs taken with lanreotide.

Frequently Asked Questions

Lanreotid Zentiva contains lanreotide, which is prescribed to control excess growth hormone in adults with acromegaly and to manage hormone‑related symptoms in patients with functional neuroendocrine tumors such as carcinoid syndrome.

Lanreotide binds to somatostatin receptors, mainly SSTR2 and SSTR5, on endocrine cells. This binding blocks adenylate cyclase, reduces cyclic AMP, and suppresses the release of growth hormone, insulin, glucagon, and various gastrointestinal hormones, thereby lowering IGF‑1 levels and alleviating tumor‑related hormone excess.

The prescribed dose of Lanreotid Zentiva is determined by the treating physician based on the individual’s condition, disease severity, and response to therapy. Dosing typically involves a subcutaneous injection administered at regular intervals, but the exact regimen must be set by a qualified healthcare professional.

Safety data for lanreotide in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential therapeutic benefit outweighs the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their clinician.

To request Lanreotid Zentiva, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative to lanreotide is octreotide, another somatostatin analog. Both agents suppress growth hormone and neuroendocrine hormone secretion, but lanreotide has a longer dosing interval (often every four weeks) whereas octreotide may require more frequent administration. Choice between them depends on patient preference, tolerability, and physician assessment.

Lanreotid Zentiva must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If temporary temperature excursions occur, consult the product’s stability guidelines before use.

The medication is supplied as a sterile injectable solution for subcutaneous injection. A healthcare professional should select an appropriate injection site (typically the abdomen or thigh), clean the area with an alcohol swab, and administer the dose using the supplied needle or an appropriate syringe, following aseptic technique.

Serious adverse events include gallstone formation, pancreatitis, severe hyperglycaemia, and allergic reactions such as anaphylaxis. Patients should be instructed to report persistent abdominal pain, signs of infection, sudden changes in blood glucose, or any symptoms of an allergic response promptly to their healthcare provider.

Lanreotid Zentiva is contraindicated in individuals with known hypersensitivity to lanreotide or any excipients in the formulation. Caution is also advised for patients with severe hepatic impairment, uncontrolled diabetes, or a history of gallbladder disease. Pregnant or nursing women should avoid use unless clearly justified by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lanreotide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT